Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 19;7(5):101356.
doi: 10.1016/j.jhepr.2025.101356. eCollection 2025 May.

AI-Cirrhosis-ECG (ACE) score for predicting decompensation and liver outcomes

Affiliations

AI-Cirrhosis-ECG (ACE) score for predicting decompensation and liver outcomes

Joseph C Ahn et al. JHEP Rep. .

Abstract

Background & aims: Accurate prediction of disease severity and prognosis are challenging in patients with cirrhosis. We evaluated whether the deep learning-based AI-Cirrhosis-ECG (ACE) score could detect hepatic decompensation and predict clinical outcomes in cirrhosis.

Methods: We analyzed 2,166 ECGs from 472 patients in a retrospective Mayo Clinic cohort, 420 patients in a prospective Mayo transplant cohort, and 341 patients in an external validation cohort from Hospital Clínic de Barcelona. The ACE score's performance was assessed using receiver-operating characteristic analysis for decompensation detection and competing risks Cox regression for outcome prediction.

Results: The ACE score showed high accuracy in detecting hepatic decompensation (area under the curve 0.933, 95% CI: 0.923-0.942) with 88.0% sensitivity and 84.3% specificity at an optimal threshold of 0.25. In multivariable analysis, each 0.1-point increase in ACE score was independently associated with increased risk of liver-related death (hazard ratio [HR] 1.44, 95% CI 1.32-1.58, p <0.001). Adding ACE to model for end-stage liver disease-sodium significantly improved prediction of adverse outcomes across all cohorts (c-statistics: retrospective cohort 0.903 vs. 0.844; prospective cohort 0.779 vs. 0.735; external validation 0.744 vs. 0.732; all p <0.001).

Conclusions: The ACE score accurately identifies hepatic decompensation and independently predicts liver-related outcomes in cirrhosis. This non-invasive tool enhances current prognostic models and may improve risk stratification in cirrhosis management.

Impact and implications: This study demonstrates the potential of artificial intelligence to enhance prognostication in liver disease, addressing the critical need for improved risk stratification in cirrhosis management. The AI-Cirrhosis-ECG (ACE) score, derived from widely available ECGs, shows promise as a non-invasive tool for detecting hepatic decompensation and predicting liver-related outcomes, which could significantly impact clinical decision-making and resource allocation in hepatology. These findings are particularly important for hepatologists, transplant surgeons, and patients with cirrhosis, as they offer a novel approach to complement existing prognostic models such as model for end-stage liver disease-sodium. In practical terms, the ACE score could be integrated into routine clinical assessments to provide more accurate risk predictions, potentially improving the timing of interventions, optimizing transplant listing decisions, and ultimately enhancing patient outcomes. However, further validation in diverse populations and integration with other established predictors is necessary before widespread clinical implementation.

Keywords: Artificial intelligence; Deep learning; Hepatic decompensation; Liver transplant; Mortality.

PubMed Disclaimer

Conflict of interest statement

No other potential conflicts of interest relevant to this article exist. Please refer to the accompanying ICMJE disclosure forms for further details.

Figures

Image 1
Graphical abstract
Fig. 1
Fig. 1
The ACE score’s association with hepatic decompensation on 12-lead ECGs. (A) Distribution of the ACE score among compensated and decompensated patients. Statistical significance determined using the Kruskal–Wallis test (p <0.01) followed by pairwise comparisons (p <0.0001 for all pairs). (B) Receiver operator characteristic curve for the ACE score's performance in discriminating compensated and decompensated patients; optimal threshold = 0.25. Area under the curve (AUC) = 0.933 (95% CI 0.923–0.942). ACE, AI-Cirrhosis-ECG; AUC, area under the curve; ECG, electrocardiogram.
Fig. 2
Fig. 2
Kaplan–Meier survival analyses by quartiles of ACE score in the retrospective Mayo cohort. (A) Probability of liver-related death over time. Statistical significance determined using the log-rank test (p <0.001). (B) Probability of liver transplant over time. Statistical significance determined using the log-rank test (p = 0.069). ACE, AI-Cirrhosis-ECG; ECG, electrocardiogram.
Fig. 3
Fig. 3
Kaplan–Meier survival analyses by quartiles of ACE score in the prospective Mayo cohort. (A) Probability of liver-related death over time. Statistical significance determined using the log-rank test (p <0.001). (B) Probability of liver transplant over time. Statistical significance determined using the log-rank test (p <0.001). ACE, AI-Cirrhosis-ECG; ECG, electrocardiogram.
Fig. 4
Fig. 4
Kaplan–Meier survival analyses by quartiles of ACE score in the Barcelona external validation cohort. Probability of liver-related death or transplant over time. Statistical significance determined using the log-rank test (p <0.001). ECG, electrocardiogram.

References

    1. Moon A.M., Singal A.G., Tapper E.B. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol. 2020;18:2650–2666. - PMC - PubMed
    1. GBD 2017 Cirrhosis Collaborators The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:245–266. - PMC - PubMed
    1. Garcia-Tsao G., Friedman S., Iredale J., et al. Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis. Hepatology. 2010;51:1445–1449. - PMC - PubMed
    1. Ginès P., Krag A., Abraldes J.G., et al. Liver cirrhosis. Lancet. 2021;398:1359–1376. - PubMed
    1. D'Amico G., Garcia-Tsao G., Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217–231. - PubMed

LinkOut - more resources